|

9MW2821 Clinical Trials

11 actively recruiting trials

▲ +1 trial since May 2026

Also known as: 9MW2821 injection

Pipeline

Phase 1: 2Phase 2: 5Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Mabwell (Shanghai) Bioscience Co., Ltd.8
  • Fudan University2
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

  • Cancer11
  • Urothelial Carcinoma3
  • Breast Cancer3
  • Advanced Urothelial Carcinoma2
  • Triple Negative Breast Cancer (TNBC)2

Other11 trials

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Phase 1/2
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 2
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
Phase 1
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Phase 3
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Phase 3
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.